-

12:51:54 PM

CRSP Stock News

CRSP - CRISPR Therapeutics AG

04/26/21 8:30 AM

Nasdaq : CRSP

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an

RHEA-AI

very positive

04/20/21 7:15 AM

Nasdaq : CRSP

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CRISPR to receive $900 million upfront payment with potential for additional $200 million

RHEA-AI

positive

04/10/21 8:31 AM

Nasdaq : CRSP

clinical trial

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s allogeneic chimeric antigen

RHEA-AI

neutral

04/06/21 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

03/10/21 5:03 PM

Nasdaq : CRSP

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for

RHEA-AI

neutral

03/03/21 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

02/16/21 4:01 PM

Nasdaq : CRSP

earnings

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 - - The first patient treated in the CLIMB-Thal-111 trial completed two years of follow-up and has enrolled in the long-term follow-up

RHEA-AI

very positive

02/05/21 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

02/01/21 8:00 AM

Nasdaq : CRSP

management

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer.

RHEA-AI

neutral

12/14/20 8:00 AM

Nasdaq : CRSP

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company

RHEA-AI

neutral

Prev 1 2 3 4 5 Next

CRSP Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitecrisprtx.com
CeoSamarth Kulkarni
Security nameCRISPR Therapeutics AG
Issue typecs
SectorManufacturing
Sic code2836
Employees410
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressBaarerstrasse 14
StateZug
CityZug
Zip6300
CountrySwitzerland
Phone41415613277

CRSP Description:

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.